Clearside Biomedical, Inc.
CLSD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -79.8% | 519.9% | -95.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91% | 95.7% | 84.6% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,463.2% | -280.3% | -2,220.3% | 1.9% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -2,064.4% | -394.9% | -2,482.8% | 1.3% |
| EPS Diluted | -7.05 | -7.95 | -8.25 | 0.095 |
| % Growth | 11.3% | 3.6% | -8,830.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |